Dynex Technologies Announces Global Partnership with ZEUS Scientific

Dynex Technologies has finalized a supply agreement with ZEUS Scientific that enables ZEUS to sell Dynex instruments to the global clinical market. This new direct partnership builds on the longstanding relationship between both companies with Dynex Technologies’ DS2, DSX, and Agility automated ELISA instrumentation and ZEUS Scientific’s range of ZEUS ELISA Test Systems, which use common reagents and universal protocols across a diverse autoimmune and infectious disease menu.
 
With an instrument base of over 6,000 systems globally, Dynex has a track record of quality, acceptance and success in automating clinical laboratories. Designed with the automated laboratory in mind, the ZEUS ELISA Test System menu (featuring over 50 U.S. Food and Drug Administration-cleared tests) optimizes workflow efficiency with simplified automation programming including multi-batching of test systems on the same plate leading to better throughput and faster integration into the laboratory.
 
“ZEUS and Dynex have long worked together in an unofficial capacity and diagnostic laboratories around the world have chosen the combined solution of ZEUS’ IVD Test Systems with Dynex’s  microplate processing systems. Now that we are directly selling and supporting the ZEUS ELISA products to the United States marketplace, in conjunction with the Dynex automation systems, ZEUS is positioned to offer the most flexible and efficient microplate testing options in the autoimmune and infectious disease markets. And providing this complete solution to our global network of distributors provides even greater reach to these solutions in diagnostic laboratories around the world,” said Chris Howard, chief commercial officer of ZEUS Scientific.
 
This strategic partnership with ZEUS Scientific allows laboratory customers a single point of contact, full solution for their automated ELISA testing needs improving the installation, training and implementation process. With multiple instrument offerings and a broad in-vitro diagnostic test menu, customers can choose a “right-sized” instrument and test menu solution that fits their needs.
 
“Partnering with ZEUS aligns with our initiatives to drive growth of our core product line by leveraging ZEUS’ ELISA menu and customer base,” remarked David Sholehvar, M.D., CEO of Dynex Technologies. “ZEUS has a reputation as a provider of quality ELISA products for autoimmune and infectious disease testing and we look forward to strengthening our relationship in our effort to deliver solutions to the market.”
 
Dynex is a market leader in automated microplate technology. Its multidisciplinary staff of approximately 125 people worldwide include design and service engineers, applications scientists, marketing, sales specialists, and precision-manufacturing experts.
 
ZEUS Scientific products are designed and manufactured to ensure optimal efficiency and accurate diagnosis to facilitate better patient care. ZEUS Scientific is based in Branchburg, N.J., and complies with the international standard ISO 13485 (2003), Health Canada Medical Device Regulations, the FDA Quality System Regulations, and the IVD 98/79/EEC.